Ipratropium Bromide for Cough in COPD

Mechanism and Efficacy

Ipratropium bromide therapy in stable patients with chronic bronchitis results in patients coughing fewer times with less severe cough, according to the American College of Chest Physicians (ACCP) 1, 3

The American College of Chest Physicians (ACCP) evidence-based guidelines give ipratropium bromide a grade A recommendation for improving cough in stable patients with chronic bronchitis 2, 3

Ipratropium bromide has demonstrated more reliable effects on cough reduction, unlike short-acting β-agonists which show inconsistent results for cough improvement, in patients with chronic bronchitis 1, 3
Ipratropium bromide significantly decreases the volume of sputum expectorated in patients with chronic bronchitis 1, 3
For acute exacerbations of chronic bronchitis, ipratropium bromide is recommended alongside short-acting β-agonists, with the addition of the other agent at maximal dose if the patient doesn't show prompt response 3, 4

For stable COPD patients with chronic cough, monitor for improvement in cough frequency and severity after starting ipratropium bromide 36 μg (2 inhalations) four times daily 1, 3
Consider adding a short-acting β-agonist for additional bronchodilation and potential cough relief if response to ipratropium bromide is inadequate 3, 4
For patients with severe airflow obstruction or frequent exacerbations, consider adding an inhaled corticosteroid with a long-acting β-agonist 1
Use ipratropium bromide or short-acting β-agonists as first-line therapy for acute exacerbations, and add the other agent at maximal dose if response is inadequate 4
Avoid theophylline during acute exacerbations 5